Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO, March 23, 2022 /PRNewswire/ — Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing…

]]>
Click here to view original post